Sugi Predict

Sugi Predict / Compounds / SCHEMBL5780089

SCHEMBL5780089

SCHEMBL5780089

O=c1c2ccccc2oc2ccc(F)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 5/20 0.67
▸ KDM4E B2RXH2 2/20 0.67
▸ ALDH1A1 P00352 2/20 0.67
▸ GLA P06280 2/20 0.67
▸ MAPT P10636 2/20 0.67
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ CYP3A4 P08684 1/20 0.67
▸ HPGD P15428 1/20 0.67
▸ PGAM1 P18669 1/20 0.67
▸ CASP1 P29466 1/20 0.67
▸ CASP7 P55210 1/20 0.67
▸ HSD17B10 Q99714 1/20 0.67
▸ NPC1 O15118 5/20 0.61
▸ RAB9A P51151 4/20 0.61
▸ POLB P06746 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ TTR P02766 2/20 0.58
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ TNKS O95271 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7678962 0.90 MEN1 (0.59) MAOAKDM4EALDH1A1GLAMAPT
SCHEMBL5781043 0.89 MAOA (0.67) MAOAKDM4EALDH1A1GLAMAPT
SCHEMBL20346620 0.85 MAOA (0.52) MAOAKDM4EALDH1A1GLAMAPT
SCHEMBL20317218 0.84 NPC1 (0.49) MAOAKDM4EALDH1A1GLAMAPT
SCHEMBL5848938 0.84 MAPT (0.59) MAOAKDM4EALDH1A1GLAMAPT
SCHEMBL20317269 0.84 MAOA (0.55) MAOAKDM4EALDH1A1GLAMAPT
SCHEMBL20317258 0.84 MAOA (0.55) MAOAKDM4EALDH1A1GLAMAPT
Xanthone SCHEMBL41161 0.82 MAOA (1.00) MAOAKDM4EALDH1A1GLAMAPT
SCHEMBL20346594 0.82 AHR (0.49) MAOAKDM4EALDH1A1GLAMAPT
Xanthone SCHEMBL29398266 0.82 MAOA (1.00) MAOAKDM4EALDH1A1GLAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227425-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION STUDIENGESELLSCHAFT KOHLE MBH (DE) 2023-07-20 — — US disclosed
US-20230227425-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION STUDIENGESELLSCHAFT KOHLE MBH (DE) 2023-07-20 — — US disclosed
US-20220002263-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION STUDIENGESELLSCHAFT KOHLE MBH (DE) 2022-01-06 — — US disclosed
EP-3856734-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION Studiengesellschaft Kohle mbH (DE) 2021-08-04 — — EP disclosed
CN-111057037-B Ultraviolet light-promoted synthesis method of xanthone compound 浙江工业大学 2021-07-23 — — CN disclosed
CN-111057037-A Ultraviolet light-promoted synthesis method of xanthone compound 浙江工业大学 2020-04-24 — — CN disclosed
US-9163002-B2 Methodology for the synthesis of xanthones UNIVERSITY OF SOUTH CAROLINA (US) 2015-10-20 — — US disclosed
US-9163002-B2 Methodology for the synthesis of xanthones UNIVERSITY OF SOUTH CAROLINA (US) 2015-10-20 — — US disclosed
US-20140107354-A1 New Methodology for the Synthesis of Xanthones UNIVERSITY OF SOUTH CAROLINA 2014-04-17 — — US disclosed
US-20140107354-A1 New Methodology for the Synthesis of Xanthones UNIVERSITY OF SOUTH CAROLINA 2014-04-17 — — US disclosed
EP-1578746-B1 OXAZOLES AS MGLUR1 ENHANCER HOFFMANN LA ROCHE (CH) 2006-06-14 — — EP disclosed
CN-1735610-A Oxazoles as mGluR1 enhancer HOFFMANN LA ROCHE (CH) 2006-02-15 — — CN disclosed
EP-1578746-A1 OXAZOLES AS MGLUR1 ENHANCER F. HOFFMANN-LA ROCHE AG (CH) 2005-09-28 — — EP disclosed
WO-2004056814-A1 OXAZOLES AS MGLUR1 ENHANCER F. HOFFMANN-LA ROCHE AG (CH) 2004-07-08 — — WO disclosed
US-20040132792-A1 Oxazoles as mGluR 1 enhancers HOFFMANN-LA ROCHE INC. 2004-07-08 — — US disclosed
EP-0307879-B1 Sulfonamido derivatives inhibiting the aldose reductase enzyme system and pharmaceutical compositions containing them BALDACCI LAB SPA (IT) 1994-06-01 — — EP disclosed
US-5066676-A Reducing vision problems related to diabetes LABORATORI BALDACCI SPA (IT) 1991-11-19 — — US disclosed
US-4927849-A TREATMENT OF DIABETES COMPLICATIONS LABORATORI BALDACCI SPA (IT) 1990-05-22 — — US disclosed
EP-0307879-A2 Sulfonamido derivatives inhibiting the aldose reductase enzyme system and pharmaceutical compositions containing them LABORATORI BALDACCI Spa (IT) 1989-03-22 — — EP disclosed
US-4086350-A FLUORO, CHLORO AND CYANO SUBSTITUTED 4-(9-XANTHENYLIDENE, 9-THIOXANTHENYLIDENE OR 11(6H)-DIBENZO(B,E)OXEPINYLIDENE)-1-METHYL-PIPERIDINES SMITHKLINE CORPORATION (US) 1978-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227425-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION CFH, DOHH, CTSH MAOA 274/4885KDM4E 739/4885ALDH1A1 283/4885
US-20220002263-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION CFH, DOHH, CTSH MAOA 274/4885KDM4E 739/4885ALDH1A1 283/4885
US-20140107354-A1 New Methodology for the Synthesis of Xanthones XDH, TYR, NISCH MAOA 68/4885KDM4E 1101/4885ALDH1A1 857/4885
US-20040132792-A1 Oxazoles as mGluR 1 enhancers GRM1, GRM2, GRIN1 MAOA 1840/4885KDM4E 643/4885ALDH1A1 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback